Summary

On November 1st, the United Kingdom (UK) published the Bletchley Declaration on the opening day of the Artificial Intelligence (AI) Safety Summit hosted at Bletchley Park, central England.This declaration, made by the UK and joined by 28 countries and international organizations, aims to promote cooperation among them regarding AI.

Why Bletchley ? It was at Bletchley Park that the Enigma code was successfully deciphered during WW2 …

International efforts are being made to examine and address the potential impact of AI systems, especially on principles such as the protection of human rights, data protection, and ethics.👉🏻 The primary focus of this declaration is on Frontier AI. These AI are defined as highly capable general-purpose AI models and specific narrow AI that could exhibit capabilities causing harm

The core concerns of the organizations revolve around the risks posed by Frontier AI, particularly in the domains of cybersecurity and biotechnology. Through international cooperation, they aim to deepen their understanding of these risks and identify actions to address them.

A regulatory approach will be considered by the participating organizations. This includes making, where appropriate, classifications and categorizations of risk based on national circumstances and applicable legal frameworks. International codes of conduct may result from this cooperation.

All AI actors are affected by this Declaration. Actors who develop Frontier AI have a significant responsibility to ensure the safety of these systems. The organizations encourage these actors to provide context-appropriate transparency and accountability in their plans to measure, monitor, and mitigate potentially harmful capabilities and associated effects, particularly to prevent misuse and issues of control, as well as the amplification of other risks.

Click here to read more

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
March 12, 2025
Clinical Trials
Biotech & Healthtech
Data Transfers
Regulations & Guidelines
Clinical Trial Sponsor

Navigating Privacy Requirements for Clinical Trials Across Jurisdictions: Focus on China

China’s data protection regulations play a crucial role in clinical trials, requiring sponsors and researchers to comply with multiple laws, including the PIPL, GCP-2020, and cross-border data transfer rules. Unlike other jurisdictions, China imposes strict consent requirements, risk assessments, and regulatory filings, making compliance a key factor when selecting trial locations and managing participant data.

October 14, 2024
Clinical Trials
Guideline

Analyzing the Similarities and Differences Between ICH-GCP and GDPR in Clinical Trials

ICH-GCP and GDPR are vital for clinical trials, setting standards for participant protection and data integrity, with distinct focuses and enforcement approaches.